scholarly journals Effect of a region-wide incorporation of an algorithm based on the 2012 international consensus guideline on the practice pattern for the management of pancreatic cystic neoplasms in an integrated health system

2018 ◽  
Vol 6 (13) ◽  
pp. 624-631
Author(s):  
Andrew Khoi Nguyen ◽  
Agathon Girgis ◽  
Timnit Tekeste ◽  
Karen Chang ◽  
Mopelola Adeyemo ◽  
...  
2021 ◽  
Vol 84 (3) ◽  
Author(s):  
A Vanden Bulcke ◽  
J Jaekers ◽  
H Topal ◽  
D Vanbeckevoort ◽  
V Vandecaveye ◽  
...  

Background and study aims : The international consensus Fukuoka guideline (Fukuoka ICG), The European evidence-based guideline on pancreatic cystic neoplasms (European EBG) and the American Gastroenterological Association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts (AGA IG) are 3 frequently cited guidelines for the risk stratification of neoplastic pancreatic cysts. The aim of this study was to assess the accuracy of detecting malignant cysts by strictly applying these guidelines retrospectively to a cohort of surgically resected pancreatic cysts. Patient and methods : 72 resected cysts were included in the analysis. Invasive carcinoma, high grade dysplasia and neuroendocrine tumour were considered as “malignant cysts” for the purpose of the study. Results : 32% of the resected cysts were malignant. The analysis showed that the Fukuoka ICG, European EBG and AGA IG had a sensitivity of 66,8%, 95,5%, 80%; a specificity of 26,8%, 11,3%, 43,8%; a positive predictive value of 31,8%, 35%, 47,1% and a negative predicted value of 61,1%, 83,3%, 77,8% respectively. The missed malignancy rate was respectively 11,3%, 1,5%, 7,7% and surgical overtreatment was respectively 48,4%, 59,1%, 34,6%. Conclusion : In this retrospective analysis, the European EBG had the lowest rate of missed malignancy at the expense of a high number of “unnecessary” resections. The Fukuoka ICG had the highest number of missed malignancy. The AGA IG showed the lowest rate of unnecessary surgery at the cost of a high number of missed malignancy. There is need to develop better biomarkers to predict the risk of malignancy.


2020 ◽  
Vol 158 (6) ◽  
pp. S-1460-S-1461
Author(s):  
Shoma Bommena ◽  
Nael Haddad ◽  
Sumit Agarwal ◽  
Sarabdeep Mann ◽  
Layth AL-Jashaami ◽  
...  

2016 ◽  
Vol 17 (2) ◽  
pp. 256-261
Author(s):  
Hyo Jung Kim ◽  
Jae Seon Kim ◽  
Jae Min Lee ◽  
Moon Kyung Joo ◽  
Beom Jae Lee ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document